Technical Analysis for LBPH - Longboard Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 21.23 | 7.66% | 1.51 |
LBPH closed up 7.66 percent on Monday, April 29, 2024, on 62 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 20 DMA Support | Bullish | 10.29% | |
| Gapped Down | Weakness | 10.29% | |
| Fell Below 50 DMA | Bearish | 7.49% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 7.49% | |
| Multiple of Ten Bearish | Other | 7.49% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 16 hours ago |
| Up 1 ATR | about 17 hours ago |
| Up 5% | about 18 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| Rose Above Upper Bollinger Band | about 20 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Neuroscience Epilepsy Psychiatry Amyotrophic Lateral Sclerosis Neurophysiology Neurology Nervous System Clinical Trial Product Neurological Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Neuroscience Epilepsy Psychiatry Amyotrophic Lateral Sclerosis Neurophysiology Neurology Nervous System Clinical Trial Product Neurological Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.15 |
| 52 Week Low | 3.6 |
| Average Volume | 515,630 |
| 200-Day Moving Average | 11.96 |
| 50-Day Moving Average | 20.04 |
| 20-Day Moving Average | 18.85 |
| 10-Day Moving Average | 18.96 |
| Average True Range | 1.39 |
| RSI (14) | 58.68 |
| ADX | 11.65 |
| +DI | 29.28 |
| -DI | 19.38 |
| Chandelier Exit (Long, 3 ATRs) | 17.74 |
| Chandelier Exit (Short, 3 ATRs) | 20.71 |
| Upper Bollinger Bands | 20.95 |
| Lower Bollinger Band | 16.75 |
| Percent B (%b) | 1.07 |
| BandWidth | 22.23 |
| MACD Line | 0.02 |
| MACD Signal Line | -0.30 |
| MACD Histogram | 0.3162 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.74 | ||||
| Resistance 3 (R3) | 23.54 | 22.51 | 23.32 | ||
| Resistance 2 (R2) | 22.51 | 21.87 | 22.61 | 23.18 | |
| Resistance 1 (R1) | 21.87 | 21.48 | 22.19 | 22.07 | 23.04 |
| Pivot Point | 20.84 | 20.84 | 21.00 | 20.94 | 20.84 |
| Support 1 (S1) | 20.20 | 20.20 | 20.52 | 20.40 | 19.42 |
| Support 2 (S2) | 19.17 | 19.81 | 19.27 | 19.28 | |
| Support 3 (S3) | 18.53 | 19.17 | 19.14 | ||
| Support 4 (S4) | 18.73 |
